BioCentury | Oct 9, 2006
Company News

Biotrace, 3M deal

MMM will acquire BOI for 130p per share, or about £52 million ($97.4 million) in cash. The price is a 16% premium to BOI's close of 112p on Oct. 3, the day before the deal...
BioCentury | Oct 9, 2006
Finance

Ebb & Flow

Biotech had a good first week of the quarter, reflected by a 3.4% jump in the BioCentury 100 Index on the back of biotech-to-biotech M&A news and robust after-market support for companies issuing new paper....
BioCentury | Sep 18, 2006
Finance

Ebb & Flow

When Amicus pulled its proposed IPO in July, the genetic disease company was hardly hurting for cash, as it had about $40 million in the bank. Nevertheless, Amicus was clearly ready to listen when existing...
BioCentury | May 15, 2006
Company News

Biotrace diagnostic news

BOI received a contract from NATO's Maintenance and Supply Agency (NAMSA) to supply BOI's nuclear, biological and chemical field laboratories to the Italian army. BOI said the contract is worth E1.74 million ($2.1 million). Biotrace...
BioCentury | Mar 13, 2006
Company News

Biotrace, Target Diagnostica srl deal

BOI's MicroSafe Group subsidiary (Rome, Italy) acquired the 61% of microbiology product company Target it did not already own for £300,000 ($526,000) in cash. Biotrace International plc (LSE:BOI), Bridgend, U.K. Target Diagnostica srl , Gessate, Italy...
BioCentury | Mar 6, 2006
Company News

Biotrace, MicroSafe Group deal

BOI acquired 62% of MicroSafe for E3.2 million ($3.8 million) in cash plus E500,000 ($593,000) in BOI shares. BOI has an option to purchase the remaining shares after three years for E2.3 million ($2.7 million)....
BioCentury | Feb 13, 2006
Company News

Biotrace deal

Industrial microbiology developer BOI sold its Ruskinn Technology business to Ruskinn's management for about £1 million ($1.8 million) in cash. The new company, Ruskinn Life Sciences Ltd., will be based in Bridgend, U.K. Ruskinn develops...
BioCentury | Jan 23, 2006
Company News

Biotrace, Pall sales and marketing update

PLL received exclusive worldwide marketing and distribution rights to BOI's Ascotec products, which monitor air quality at pharmaceutical production facilities. Biotrace International plc (LSE:BOI), Bridgend, U.K. Pall Corp. (PLL), New York, N.Y. Business: Supply/Service WIR...
BioCentury | Jul 12, 2004
Finance

Ebb & Flow

With the third quarter underway, those looking for a reading on the health of the IPO window in the U.S. may get some clear signals this week. Two companies - TolerRx and Phase Forward - are expected...
BioCentury | Sep 8, 2003
Finance

Ebb & Flow

Despite a 15-month absence from banking conferences on Wall Street, ImClone (IMCL) didn't use its opportunity at last Thursday's 10th Annual NewsMakers in the Biotech Industry conference to throw any bones to a hungry audience....
Items per page:
1 - 10 of 41
BioCentury | Oct 9, 2006
Company News

Biotrace, 3M deal

MMM will acquire BOI for 130p per share, or about £52 million ($97.4 million) in cash. The price is a 16% premium to BOI's close of 112p on Oct. 3, the day before the deal...
BioCentury | Oct 9, 2006
Finance

Ebb & Flow

Biotech had a good first week of the quarter, reflected by a 3.4% jump in the BioCentury 100 Index on the back of biotech-to-biotech M&A news and robust after-market support for companies issuing new paper....
BioCentury | Sep 18, 2006
Finance

Ebb & Flow

When Amicus pulled its proposed IPO in July, the genetic disease company was hardly hurting for cash, as it had about $40 million in the bank. Nevertheless, Amicus was clearly ready to listen when existing...
BioCentury | May 15, 2006
Company News

Biotrace diagnostic news

BOI received a contract from NATO's Maintenance and Supply Agency (NAMSA) to supply BOI's nuclear, biological and chemical field laboratories to the Italian army. BOI said the contract is worth E1.74 million ($2.1 million). Biotrace...
BioCentury | Mar 13, 2006
Company News

Biotrace, Target Diagnostica srl deal

BOI's MicroSafe Group subsidiary (Rome, Italy) acquired the 61% of microbiology product company Target it did not already own for £300,000 ($526,000) in cash. Biotrace International plc (LSE:BOI), Bridgend, U.K. Target Diagnostica srl , Gessate, Italy...
BioCentury | Mar 6, 2006
Company News

Biotrace, MicroSafe Group deal

BOI acquired 62% of MicroSafe for E3.2 million ($3.8 million) in cash plus E500,000 ($593,000) in BOI shares. BOI has an option to purchase the remaining shares after three years for E2.3 million ($2.7 million)....
BioCentury | Feb 13, 2006
Company News

Biotrace deal

Industrial microbiology developer BOI sold its Ruskinn Technology business to Ruskinn's management for about £1 million ($1.8 million) in cash. The new company, Ruskinn Life Sciences Ltd., will be based in Bridgend, U.K. Ruskinn develops...
BioCentury | Jan 23, 2006
Company News

Biotrace, Pall sales and marketing update

PLL received exclusive worldwide marketing and distribution rights to BOI's Ascotec products, which monitor air quality at pharmaceutical production facilities. Biotrace International plc (LSE:BOI), Bridgend, U.K. Pall Corp. (PLL), New York, N.Y. Business: Supply/Service WIR...
BioCentury | Jul 12, 2004
Finance

Ebb & Flow

With the third quarter underway, those looking for a reading on the health of the IPO window in the U.S. may get some clear signals this week. Two companies - TolerRx and Phase Forward - are expected...
BioCentury | Sep 8, 2003
Finance

Ebb & Flow

Despite a 15-month absence from banking conferences on Wall Street, ImClone (IMCL) didn't use its opportunity at last Thursday's 10th Annual NewsMakers in the Biotech Industry conference to throw any bones to a hungry audience....
Items per page:
1 - 10 of 41